secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXELIXIS, INC. (EXEL)
CIK:        0000939767
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0000939767-23-000078
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exelixis Q2 revenue $469.8M, GAAP EPS $0.25; CABOMETYX drives growth
--------------------------------------------------------------------

- Total revenues $469.8M (+12% YoY); net product revenues $409.6M (+18% YoY).
- GAAP diluted EPS $0.25; non-GAAP diluted EPS $0.31, vs $0.22 and $0.28 last year.
- CABOMETYX remains top TKI in RCC; growth driven by first-line combo with nivolumab.
- Pipeline advances: zanzalintinib STELLAR-001 enrollment complete; XB002 dose selected.
- Upcoming catalysts: CONTACT-02 readout, COSMIC-313 OS analysis, R&D Day Dec 12.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/0000939767-23-000078-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/939767/000093976723000078/exel-20230801.htm
  HTML page:      https://secwatch.observer/filing/0000939767-23-000078

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer